BAMCO Inc’s AbCellera Biologics ABCL Stock Holding History

BAMCO Inc’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-99,621	Closed	-$4.01M	–	395
2020 Q4	$4.01M	Buy	+99,621	New	+$4.56M	0.01%	305

Other funds holding ABCL

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BAMCO Inc's ABCL Position: Q1 2021 in Review

BAMCO Inc sold out of AbCellera Biologics (ABCL) in Q1 2021, closing a stake of 99,621 shares — an estimated $4.01M sold.

BAMCO Inc first reported a position in ABCL in Q4 2020 and held it in 1 quarter. The position peaked at $4.01M in Q4 2020. 86 funds tracked by Wall St. Rank hold ABCL as of Q1 2021.

BAMCO Inc reported no remaining AbCellera Biologics position as of Q1 2021 after selling out during the quarter.
BAMCO Inc sold 99,621 AbCellera Biologics shares in Q1 2021, an estimated $4.01M.
BAMCO Inc first reported a position in AbCellera Biologics in Q4 2020 and held it in 1 quarter.
BAMCO Inc's AbCellera Biologics position peaked at $4.01M in Q4 2020.
86 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2021.

Based on BAMCO Inc's 13F filing for Q1 2021, filed 19 May 2021.